Cancer immunotherapy, a treatment approach that has gained momentum over the past few years, only helps a small fraction of patients. But researchers from the Johns Hopkins University School of Medicine have developed a nanoparticle that may one day help expand the patient population that benefits from immunotherapy.
Immunotherapy usually falls into 1 of 2 categories: it either prevents cancer cells from hiding from the patient’s immune system or it stimulates the body’s T cells to fight against tumors. The team from Johns Hopkins hoped to devise a nanoparticle platform that could do both.
Get the full story at our sister site, Drug Delivery Business News.